The global biopharmaceuticals market accounted for $ 160,440.4 million in 2014, and it is expected to grow with a CAGR of 9.6% during 2015-2020. The monoclonal antibodies market segment dominated the global biopharmaceuticals market in 2014 with about 25.8% share. The oncology segment accounted for the largest market in the global biopharmaceuticals market in 2014; and is expected to witness growth with 11.1% CAGR during the period 2015-2020.
The global biopharmaceuticals market is growing with a high growth rate, due to increasing geriatric population, increasing R&D investments, increasing prevalence of chronic diseases, and technological advancements in biopharmaceuticals which has helped in curing diseases with no available treatment. The restraints associated with the global biopharmaceuticals market include high cost of biopharmaceuticals and side effects, such as breathing problems, sore throat, allergic reactions, itching, and rashes due to the consumption of biopharmaceuticals.
The Indian pharmaceuticals market increased at a CAGR of 17.46% during 2005-16 with the market increasing from US$ 6 billion in 2005 to US$ 36.7 billion in 2016 and is expected to expand at a CAGR of 15.92 per cent to US$ 55 billion by 2020. By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size. India’s cost of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over others. With 70 per cent of market share (in terms of revenues), generic drugs form the largest segment of the Indian pharmaceutical sector. India supply 20 per cent of global generic medicines market exports in terms of volume, making the country the largest provider of generic medicines globally and expected to expand even further in coming years. Over the Counter (OTC) medicines and patented drugs constitute 21 per cent and 9 per cent, respectively, of total market revenues of US$ 20 billion.
Biopharmaceuticals are in huge demand due to the increasing prevalence of chronic diseases, which is one of the key drivers, fuelling the growth of the global biopharmaceuticals market. Chronic diseases are increasing due to unhealthy lifestyle, poor diet, excess alcohol consumption, and lack of physical activity. The increase in chronic diseases worldwide is leading to the growth in the number of hospitalization cases, which is fuelling the demand for biopharmaceuticals.
Students trained in Biopharmaceutical Technology will be able to take up technical and executive positions in the biopharmaceutical and related supporting industries. Graduates will find work with companies employing bio-processing as well as traditional production techniques such as: Pharmaceutical, Cosmetic, Nutraceutical, Food and Beverage production, etc.
Biocon, Hindustan Unilever Ltd, The Himalaya Drug Company, Sami Lab Ltd, Acquity Labs Pvt Ltd, Aristogene, Connexios Life Sciences, GangaGen Biotechnologies, Genotypic Technology, Celest Pharma, Beckman Coulter, Sartorius AG, GE Healthcare, Bristol Myers Squibb India Ltd , Dr. Reddy’s Lab, GSK, Shantha Biotech, Novozymes, Ranbaxy, Cipla, Novortis, Pfizer, Merck, Anglo-French Drugs, Strand Life Sciences, Orchid Pharma, Jubilant Biosys, Shasun Biopharma, Dharma Life Sciences, Cerner Healthcare, Quintiles, Reliance Life Sciences, United Biotech, Kemwell Biopharma, Cadila Pharma, Bangalore Pharmaceutical and Research Lab, Advinus Therapeutics, AstraZeneca, Roche Ltd, Promega Corporation, Natural Remedies, Eli Lilly, Piramal, etc.
|Sl. No.||Name and address of the Institution||Contact Person / Details||Code|
|1||M S Ramaiah Institute of Technology
MSR College Road, MSR Nagar , Mathikere
Bengaluru – 560054.
|Dr. Bindu S